Alzamend Neuro, Inc. (ALZN)

MorphoSys AG Statistics

Total Valuation

Alzamend Neuro has a market cap or net worth of $6.89 million. The enterprise value is $2.94 million.

Market Cap	6.89M
Enterprise Value	2.94M

Important Dates

The next estimated earnings date is Wednesday, September 10, 2025, after market close.

Earnings Date	Sep 10, 2025
Ex-Dividend Date	n/a

Share Statistics

Alzamend Neuro has 2.90 million shares outstanding. The number of shares has increased by 499.67% in one year.

Current Share Class	2.90M
Shares Outstanding	2.90M
Shares Change (YoY)	+499.67%
Shares Change (QoQ)	+16.01%
Owned by Insiders (%)	0.21%
Owned by Institutions (%)	0.51%
Float	2.88M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.47
P/TBV Ratio	1.74
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.58

Current Ratio	6.58
Quick Ratio	6.22
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-249.42

Financial Efficiency

Return on equity (ROE) is -657.17% and return on invested capital (ROIC) is -335.63%.

Return on Equity (ROE)	-657.17%
Return on Assets (ROA)	-107.38%
Return on Invested Capital (ROIC)	-335.63%
Return on Capital Employed (ROCE)	-113.32%
Revenue Per Employee	n/a
Profits Per Employee	-$729,298
Employee Count	7
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -91.89% in the last 52 weeks. The beta is -0.32, so Alzamend Neuro's price volatility has been lower than the market average.

Beta (5Y)	-0.32
52-Week Price Change	-91.89%
50-Day Moving Average	3.15
200-Day Moving Average	7.95
Relative Strength Index (RSI)	33.06
Average Volume (20 Days)	241,703

Short Selling Information

The latest short interest is 88,987, so 3.07% of the outstanding shares have been sold short.

Short Interest	88,987
Short Previous Month	87,004
Short % of Shares Out	3.07%
Short % of Float	3.09%
Short Ratio (days to cover)	0.37

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-4.50M
Pretax Income	-9.95M
Net Income	-5.11M
EBITDA	-4.45M
EBIT	-4.50M
Earnings Per Share (EPS)	-$11.32

Balance Sheet

The company has $3.95 million in cash and n/a in debt, giving a net cash position of $3.95 million or $1.36 per share.

Cash & Cash Equivalents	3.95M
Total Debt	n/a
Net Cash	3.95M
Net Cash Per Share	$1.36
Equity (Book Value)	3.97M
Book Value Per Share	5.10
Working Capital	3.54M

Cash Flow

In the last 12 months, operating cash flow was -$6.57 million and capital expenditures -$300,000, giving a free cash flow of -$6.87 million.

Operating Cash Flow	-6.57M
Capital Expenditures	-300,000
Free Cash Flow	-6.87M
FCF Per Share	-$2.37

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Alzamend Neuro does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-499.67%
Shareholder Yield	-499.67%
Earnings Yield	-74.06%
FCF Yield	-99.63%

Analyst Forecast

The average price target for Alzamend Neuro is $180.00, which is 7,463.03% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$180.00
Price Target Difference	7,463.03%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 12, 2025. It was a reverse split with a ratio of 1:9.

Last Split Date	May 12, 2025
Split Type	Reverse
Split Ratio	1:9

Scores

Altman Z-Score	n/a
Piotroski F-Score	1